<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089258</url>
  </required_header>
  <id_info>
    <org_study_id>04-050</org_study_id>
    <secondary_id>MSKCC-04050</secondary_id>
    <nct_id>NCT00089258</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment</brief_title>
  <official_title>Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and&#xD;
      either kill them or deliver tumor-killing substances to them without harming normal cells.&#xD;
      Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal&#xD;
      antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining&#xD;
      different types of biological therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and&#xD;
      sargramostim together with monoclonal antibody 3F8 works in treating patients with&#xD;
      neuroblastoma that has not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of beta-glucan, isotretinoin, and sargramostim (GM-CSF) in&#xD;
           enhancing monoclonal antibody 3F8-mediated ablation in patients with high-risk&#xD;
           refractory neuroblastoma.&#xD;
&#xD;
        -  Determine the antitumor activity of this regimen, in terms of assessing disease status&#xD;
           in the bone marrow by real-time quantitative reverse transcription polymerase chain&#xD;
           reaction, in these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study. Patients are stratified according to refractory disease&#xD;
      (primary refractory [never had disease progression or disease recurrence] vs secondary&#xD;
      refractory [recurrent disease that did not respond completely to reinduction therapy]).&#xD;
&#xD;
        -  Courses 1 and 2: Patients receive sargramostim (GM-CSF) subcutaneously once daily on&#xD;
           days -5 to 11. Patients also receive oral beta-glucan once daily on days -2 to 11 and&#xD;
           monoclonal antibody (MOAB) 3F8 IV over 30-90 minutes on days 0-4 and 7-11.&#xD;
&#xD;
        -  Courses 3 and 4: Patients receive GM-CSF, beta-glucan, and MOAB 3F8 as above. Patients&#xD;
           also receive oral isotretinoin twice daily on days -2 to 11.&#xD;
&#xD;
      Treatment repeats every 2-4 weeks for 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27-74 patients (10-33 for stratum 1 and 17-41 for stratum 2)&#xD;
      will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease response as assessed by PT-PC at the end of 4 courses</measure>
  </primary_outcome>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>beta-glucan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody 3F8</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of neuroblastoma, as defined by 1 of the following:&#xD;
&#xD;
               -  Histologically confirmed disease&#xD;
&#xD;
               -  Bone marrow metastases plus high urine catecholamines&#xD;
&#xD;
          -  High-risk disease meeting 1 of the following stage criteria:&#xD;
&#xD;
               -  Stage IV, with 1 of the following:&#xD;
&#xD;
                    -  Any age with MYCN amplification&#xD;
&#xD;
                    -  &gt; 18 months of age without MYCN amplification&#xD;
&#xD;
               -  Stage III, with both of the following:&#xD;
&#xD;
                    -  Any age with MYCN amplification&#xD;
&#xD;
                    -  Unresectable disease&#xD;
&#xD;
               -  Stage 4S with MYCN amplification&#xD;
&#xD;
          -  Measurable or evaluable soft tissue disease&#xD;
&#xD;
          -  Relapsed disease resistant to standard induction chemotherapy and salvage therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No severe hepatic toxicity ≥ grade 3&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  No severe renal toxicity ≥ grade 3&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe cardiac toxicity ≥ grade 3&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe pulmonary toxicity ≥ grade 3&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No severe neurologic toxicity ≥ grade 3&#xD;
&#xD;
          -  No severe gastrointestinal toxicity ≥ grade 3&#xD;
&#xD;
          -  No other severe major organ dysfunction except ototoxicity&#xD;
&#xD;
          -  No history of allergy to mouse proteins&#xD;
&#xD;
          -  No active life-threatening infection&#xD;
&#xD;
          -  No human anti-mouse antibody titer &gt; 1,000 ELISA units/mL&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nai-Kong V. Cheung, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

